Venus Remedies Limited has informed the Exchange regarding a press release dated September 20, 2023, titled "Venus Remedies extends its oncology portfolio in South Eastern Europe with Serbian marketing approval for gemcitabine and docetaxel.".
Venus Remedies Limited has informed the Exchange regarding a press release dated September 20, 2023, titled "Venus Remedies extends its oncology portfolio in South Eastern Europe with Serbian marketing approval for gemcitabine and docetaxel.".